[The place of "monocomponent" insulins in diabetes mellitus therapy].
The chemical and biochemical properties of highly purified insulin (termed "monocomponent insulin") are discussed. The clinical indications for this mc-insulin are immunologic side effects of conventional insulin therapy such as resistance, allergy and lipoatrophy. Furthermore, highly purified insulins can be tried in high insulin requirement, in juvenile diabetes and intermittent insulin therapy. Case histories for these clinical indications are presented. It is advised that the use of mc-insulin should be restricted to precise clinical indications until enough pure pig insulin is available for treatment of all insulin-dependent diabetics.
D000818:Animals; D002417:Cattle; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000517:prevention & control; D005260:Female; D006801:Humans; D007328:Insulin / Q000302:isolation & purification* / Q000627:therapeutic use; D007330:Insulin Antibodies; D008060:Lipodystrophy / Q000517:prevention & control; D008297:Male; D012877:Skin Manifestations; D013552:Swine
D007328:Insulin; D007330:Insulin Antibodies
Der Platz der "Monkomponent"-Insuline in der Therapie des Diabetes mellitus